Camber Pharmaceuticals recalls
Camber Pharmaceuticals appears in 5 official U.S. recall notices indexed by RecallRadar, most recently on 2023-05-17.
Company names are normalized from agency data (legal suffixes removed), so related firms may appear under separate pages.
Recall summary
| Recall notices | 5 |
|---|---|
| Published | 2019-03-27 to 2023-05-17 |
| By agency | FDA Drug (5) |
| By classification | Class II (3), Class I (1), Class III (1) |
| By status | ongoing (4), terminated (1) |
| Distribution named in notices | US |
Recalls
- Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 0885…
FDA Drug · Class I · 2023-05-17 · Camber Pharmaceuticals
Reason: Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product. - Lacosamide Oral Solution, USP, CV, 10mg/mL, packaged in 200 mL bottle, Rx Only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway,…
FDA Drug · Class III · 2022-12-21 · Camber Pharmaceuticals
Reason: Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content - Losartan Potassium Tablets USP, 100 mg, Rx only, a) 30 count (NDC 31722-702-30), b) 90 count (NDC 31722-702-30), c) 1000 count (NDC 31722-7…
FDA Drug · Class II · 2019-03-27 · Camber Pharmaceuticals
Reason: CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient - Losartan Potassium Tablets USP, 25 mg, Rx only, a) 90 count (NDC 31722-700-90), b) 500 count (NDC 31722-700-05) and c) 1000 count (NDC 3172…
FDA Drug · Class II · 2019-03-27 · Camber Pharmaceuticals
Reason: CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient - Losartan Potassium Tablets USP, 50 mg, Rx only, a) 30 count (NDC 31722-701-30), b) 90 count (NDC 31722-701-90), c) 1000 count (NDC 31722-70…
FDA Drug · Class II · 2019-03-27 · Camber Pharmaceuticals
Reason: CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient